Jingyin Yan
Nephrology · Houston, TXNPI 1982865721
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $25,107 of the $34,875 with a category attached, or 72.0%. 13 manufacturers reported payments, led by Travere Therapeutics, Inc. at 37.2% of the total. Among nephrology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 81 payments — averaging $430.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$13K
- Otsuka America Pharmaceutical, Inc.$7K
- Calliditas Therapeutics US Inc.$5K
- Fresenius USA Marketing, Inc.$4K
- Mallinckrodt Enterprises LLC$3K
- Access Vascular Inc$650
- plus $1K from 7 others
Across 1 payment — averaging $15,595 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$16K
What the payments were for
- Consulting fees$25,10772%
- Speaking & faculty fees$3,0009%
- Travel & lodging$3,2679%
- Food & beverage$3,2319%
- Education$2691%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 26 | $12,973 |
| Otsuka America Pharmaceutical, Inc. | 16 | $7,371 |
| Calliditas Therapeutics US Inc. | 4 | $5,072 |
| Fresenius USA Marketing, Inc. | 7 | $4,338 |
| Mallinckrodt Enterprises LLC | 3 | $3,152 |
| Access Vascular Inc | 1 | $650 |
| AstraZeneca | 8 | $339 |
| GSK | 5 | $322 |
| Medtronic | 3 | $222 |
| Mallinckrodt Hospital Products Inc. | 2 | $134 |
| Amgen | 1 | $124 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $121 |
| Vifor Pharma, Inc. | 3 | $57 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TARPEYO$5,072
- Velphoro$4,268
- ACTHAR$3,214
- Filspari$828
- HYDROPICC$650
- HYDROMID$650
- HYDROPICC DUAL LUMEN$650
- VANNAS DEEP ACCESS VASCULAR SCISSORS$650
- LOKELMA$232
- BENLYSTA$124
- KRYSTEXXA$124
- ELLIPSYS VASCULAR ACCESS SYSTEM$122
- JYNARQUE$114
How this compares
$34,875 in reported general payments places this provider in the 90th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 19 | $60,421 |
| JardianceEmpagliflozin | 34 | $40,271 |
| FarxigaDapagliflozin Propanediol | 26 | $40,122 |
| Sevelamer Carbonate | 36 | $23,162 |
| LokelmaSodium Zirconium Cyclosilicate | 19 | $22,558 |
| Nifedipine ErNifedipine | 42 | $2,101 |
| ProsolParenteral Amino Acid 20% No.1 | 21 | $2,026 |
| Calcium Acetate | 18 | $1,286 |
| Potassium Citrate ErPotassium Citrate | 20 | $1,258 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 26 | $465 |
| Carvedilol | 47 | $396 |
| Tamsulosin Hcl | 23 | $303 |
| Losartan Potassium | 34 | $268 |
| Gabapentin | 14 | $252 |
| Furosemide | 35 | $250 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $339 | $62,68045 claims |
| Fresenius USA Marketing, Inc.Velphoro | $4,338 | $60,42119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,070 nephrology providers in Texas.
Other nephrology in Houston
- Sreedhar MandayamHouston$752K
- Christopher KwohHouston$467K
- Wolfgang WinkelmayerHouston$462K
- Namrata GoelHouston$426K
- Dana MitchellHouston$344K
- Ramachandra MalyaHouston$312K
- John ForingerHouston$215K
- Biruh WorkenehHouston$185K
- Horacio AdrogueHouston$122K
- Anand SaranathanHouston$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.